Nisa Investment Advisors LLC Lowers Position in AstraZeneca PLC (NASDAQ:AZN)

Nisa Investment Advisors LLC trimmed its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 63.9% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 650 shares of the company’s stock after selling 1,150 shares during the period. Nisa Investment Advisors LLC’s holdings in AstraZeneca were worth $43,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently bought and sold shares of AZN. Stratos Wealth Advisors LLC grew its position in shares of AstraZeneca by 2.0% during the third quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock valued at $522,000 after purchasing an additional 133 shares in the last quarter. Crumly & Associates Inc. boosted its stake in AstraZeneca by 2.2% during the third quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock valued at $518,000 after buying an additional 143 shares during the last quarter. Diversify Wealth Management LLC grew its holdings in AstraZeneca by 3.6% during the 4th quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company’s stock valued at $295,000 after buying an additional 153 shares in the last quarter. Veery Capital LLC increased its stake in AstraZeneca by 4.7% in the 4th quarter. Veery Capital LLC now owns 3,503 shares of the company’s stock worth $230,000 after acquiring an additional 157 shares during the last quarter. Finally, Harbour Investments Inc. raised its holdings in shares of AstraZeneca by 1.9% during the 3rd quarter. Harbour Investments Inc. now owns 8,805 shares of the company’s stock worth $686,000 after acquiring an additional 160 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on AZN. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $89.75.

AstraZeneca Stock Down 0.7 %

Shares of AZN opened at $70.76 on Friday. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The business has a fifty day moving average of $66.98 and a 200 day moving average of $73.97. The company has a market cap of $219.43 billion, a PE ratio of 33.86, a P/E/G ratio of 1.17 and a beta of 0.46. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.03. The business had revenue of $13.57 billion for the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The business’s revenue for the quarter was up 18.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.87 earnings per share. On average, sell-side analysts expect that AstraZeneca PLC will post 4.13 EPS for the current year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.